Fierce Biotech

Genentech executes another round of layoffs, with 3 VPs axed

Genentech vice presidents Vishva Dixit, M.D., Man-Wah Tan, Ph.D., and Todd McDevitt, Ph.D., are among the casualties in ...

Former Genentech exec moves company to Bay Area from Colorado with $400 million in the bank

A company competing with Novartis and Merck to treat people with chronic myeloid leukemia moved from Colorado to the Bay Area ...

Genentech layoffs include elimination of infectious disease department

In the latest restructuring, Genentech will lose 29-year veteran Vishva Dixit, the vice president of its physiological ...
Fierce Pharma

Lilly, Biogen, Eisai and Genentech sponsor new ‘Let’s Talk Alzheimer’s’ podcast

Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become ...
Scientific American

Aviv Regev

The biotech executive talks about how we are currently at an inflection point in biomedical science and how frustration can ...
STAT

Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Applicat ...